The estimated Net Worth of Patricia C Hirano is at least $7.58 Million dollars as of 28 August 2024. Ms. Hirano owns over 10,705 units of Soleno Therapeutics Inc stock worth over $5,442,903 and over the last 6 years she sold SLNO stock worth over $1,783,283. In addition, she makes $355,945 as Vice President - Regulatory Affairs at Soleno Therapeutics Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Ms. Hirano SLNO stock SEC Form 4 insiders trading
Patricia has made over 9 trades of the Soleno Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently she sold 10,705 units of SLNO stock worth $507,738 on 28 August 2024.
The largest trade she's ever made was buying 20,000 units of Soleno Therapeutics Inc stock on 31 March 2022 worth over $971,600. On average, Patricia trades about 2,926 units every 40 days since 2019. As of 28 August 2024 she still owns at least 112,040 units of Soleno Therapeutics Inc stock.
You can see the complete history of Ms. Hirano stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Patricia Hirano biography
Patricia C. Hirano serves as Vice President - Regulatory Affairs of the Company. She joined the Company as Vice President, Regulatory Affairs in January, 2019. From April, 2017 through December, 2018, Ms. Hirano served as Head of Regulatory Affairs and Quality at the Company in a consulting capacity. Prior to this, she was an independent regulatory consultant since April, 2010, providing regulatory affairs, project management, and clinical operations expertise to biopharmaceutical and biosimilar companies. Her experience encompasses the development of pharmaceuticals, biologics, and drug-device combination products for the treatment of oncology, cardiovascular, neurology, pulmonary/allergy, and endocrine/metabolic diseases. Prior to 2010, she held various positions of increasing responsibility at the Company, Titan Pharmaceuticals, Inc., PRTM (now PWC), CV Therapeutics, Inc. (acquired by Gilead), and Matrix Pharmaceutical, Inc. (acquired by Chiron Corp). She has also been the coordinator of the Bay Area Compliance Discussion Group since 1998. She has been a Director at The Big C Society since April 2014.
What is the salary of Patricia Hirano?
As the Vice President - Regulatory Affairs of Soleno Therapeutics Inc, the total compensation of Patricia Hirano at Soleno Therapeutics Inc is $355,945. There are 2 executives at Soleno Therapeutics Inc getting paid more, with Anish Bhatnagar having the highest compensation of $822,089.
How old is Patricia Hirano?
Patricia Hirano is 54, she's been the Vice President - Regulatory Affairs of Soleno Therapeutics Inc since 2019. There are 6 older and 4 younger executives at Soleno Therapeutics Inc. The oldest executive at Soleno Therapeutics Inc is Ernest Mario, 81, who is the Independent Chairman of the Board.
What's Patricia Hirano's mailing address?
Patricia's mailing address filed with the SEC is 203 REDWOOD SHORES PKWY, STE 500, , REDWOOD CITY, CA, 94065.
Insiders trading at Soleno Therapeutics Inc
Over the last 9 years, insiders at Soleno Therapeutics Inc have traded over $134,327,999 worth of Soleno Therapeutics Inc stock and bought 56,592,152 units worth $70,324,676 . The most active insiders traders include Advisors Llcperceptive Life..., Jack W Schuler, and Andrew Sinclair. On average, Soleno Therapeutics Inc executives and independent directors trade stock every 29 days with the average trade being worth of $36,911,570. The most recent stock trade was executed by Kristen Yen on 28 August 2024, trading 10,705 units of SLNO stock currently worth $507,738.
What does Soleno Therapeutics Inc do?
soleno therapeutics, inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. the company is currently advancing its lead candidate, dccr, a once-daily oral tablet for the treatment of pws, into a phase iii clinical development program in early 2018.
What does Soleno Therapeutics Inc's logo look like?
Complete history of Ms. Hirano stock trades at Soleno Therapeutics Inc
Soleno Therapeutics Inc executives and stock owners
Soleno Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Anish Bhatnagar,
President, Chief Executive Officer, Director -
Dr. Anish Bhatnagar,
Pres, CEO, COO & Director -
Patricia Hirano,
Vice President - Regulatory Affairs -
Kristen Yen,
Vice President - Clinical Operations -
James H. MacKaness,
Chief Financial Officer -
Ernest Mario,
Independent Chairman of the Board -
William Harris,
Independent Director -
Gwen Melincoff,
Independent Director -
Birgitte Volck,
Independent Director -
Andrew Sinclair,
Independent Director -
Dr. Neil M. Cowen M.B.A., Ph.D., MBA,
Sr. VP of Drug Devel. -
Anthony Wondka,
Sr. VP & GM -
Dawn Carter Bir,
-
Jack W Schuler,
-
Larry N Feinberg,
10% owner -
Opportunity, Llc Vivo Oppor...,
-
Jonathan Wolter,
Chief Financial Officer -
Stephen Kirnon,
Director -
Mahendra Shah,
Director -
Rajen Dalal,
Director -
Edgar Engleman,
Director -
Ventures V, Llc Vivo,
10% owner -
Steinar J Engelsen,
Director -
James Walter Glasheen,
Director -
Stuart J Collinson,
Director -
Ventures V, Llc Vivo Ventur...,
-
Raymond W. Urbanski,
CHIEF DEVELOPMENT OFFICER -
Management Vii Llctechnolog...,
-
Mangement Llcbioasia Invest...,
-
Larry Noracle Partners Lp F...,
-
Llp Abingworth,
10% owner -
Ventures V, Llc Vivo Ventur...,
-
Group Inc.Carlyle Holdings ...,
-
Meredith Manning,
Chief Commercial Officer -
Michael F. Huang,
Sr. VP of Clinical Development -
Matthew Pauls,
-
Group Inc.Carlyle Holdings ...,
-
Advisors Llcperceptive Life...,
-
James H Mackaness,
CHIEF FINANCIAL OFFICER